Home › Peptides A to Z › OctreotideWhat is Octreotide? An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Octreotide in the library · · Human Trials · What are peptides?
256 registered trials · 1159 indexed papers · 1285 human / 35 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Type: Somatostatin analog peptide.
Human research The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Octreotide is one of its interventions, or is named in the study title or subject headings.
Listing a study does not mean it showed a benefit, and it is not medical advice.
Registered human trials (256) Trial Phase Status Year Enrolled Human Models of Selective Insulin Resistance: Pancreatic Clamp Phase 1 not yet recruiting 2027 36 Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema Phase 1 withdrawn 2026 An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly recruiting 2026 200 A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) Phase 1 completed 2026 18 A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly Phase 3 not yet recruiting 2026 154 Hoffa's Fat Pad Impingement (HFPI) Phase 4 recruiting 2026 62 Octreotide Microspheres for Preventing Pancreatic Fistula Phase 3 not yet recruiting 2026 230 18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms not yet recruiting 2026 152 Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors Phase 3 recruiting 2025 166 Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET Phase 3 recruiting 2025 240 177Lu-DOTATATE for Recurrent Meningioma Phase 2 recruiting 2025 136 Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Phase 2/Phase 3 recruiting 2025 298 Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome completed 2025 60 Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Phase 2 terminated 2025 2 Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA) Phase 4 recruiting 2025 400 Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial) Phase 4 not yet recruiting 2025 80 Graded Insulin Suppression Test P&F Phase 1 completed 2024 20 A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly Phase 2 completed 2024 78 Direct Versus Indirect Effect of Amino Acids on Hepatokines active not recruiting 2024 30 Outcome of ADPKD With Octreotide LAR active not recruiting 2024 70 A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET) Phase 2 recruiting 2024 90 Dexamethasone/Pancreatic Clamp P&F Phase 1 withdrawn 2024 A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors not yet recruiting 2024 500 An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. Phase 3 recruiting 2023 220 Pancreatic Clamp in NAFLD Phase 1 completed 2023 18 A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs Phase 3 recruiting 2023 184 Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Phase 4 recruiting 2023 270 Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements. Phase 2 unknown 2023 62 A Single-dose Study of Octreotide Injection in Healthy Adult Subjects Phase 1 completed 2023 56 Role of Octreotide in Non Variceal Bleeding Phase 2/Phase 3 unknown 2023 56 Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Phase 3 active not recruiting 2022 343 A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD Phase 2/Phase 3 active not recruiting 2022 71 Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression Phase 2/Phase 3 recruiting 2022 400 A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Phase 1 terminated 2022 19 A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs Phase 3 active not recruiting 2022 196 A Feasibility Study of Octreotide Infusion During Liver Transplant. Phase 2 unknown 2022 30 Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study Phase 4 unknown 2022 184 A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET Phase 3 active not recruiting 2021 332 Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients Phase 2 active not recruiting 2021 69 Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer Phase 2 completed 2021 20
Peer-reviewed studies (1159) Paper Authors Journal Year Type A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acids Yu YH et al. Frontiers in endocrinology 2026 Randomized Controlled Trial Lesion-level Quantitative Post-therapy SPECT/CT During (177)Lu-DOTATATE PRRT for NET Liver Metastases Konishi K et al. Anticancer research 2026 Observational Study Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [(177)Lu]Lu-DOTATATE: results from the LuDO-N trial Park SWS et al. European journal of nuclear medicine and molecular imaging 2026 Clinical Trial Targeted Alpha Therapy With [ 225 Ac]Ac-DOTATATE Versus Salvage Retreatment PRRT With [ 177 Lu]Lu-DOTATATE in Progressive Metastatic Neuroendocrine Tumor Patients After Initial Course of [ 177 Lu]Lu-DOTATATE Treatment : An Observational Study Comparing the Therapeutic Response, Survival, and Clinical Toxicity Agrawal R et al. Clinical nuclear medicine 2026 Observational Study Pharmacokinetics and Dosimetry of (177)Lu-DOTATATE in Patients with Advanced Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumors: Results from a Substudy of the Phase 3 XT-XTR008-3-01 Trial Ma G et al. Molecular pharmaceutics 2026 Observational Study Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [(225)Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs Sgouros G et al. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026 Randomized Controlled Trial [(177)Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial Baudin E et al. The Lancet. Oncology 2026 Randomized Controlled Trial Integration of ⁶⁸Ga-DOTA-TOC PET/CT into radiotherapy planning for intracranial meningiomas: A precision-imaging approach to tumor delineation Usmani S et al. Annals of nuclear medicine 2026 Observational Study [(177)Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial Chan DL et al. European journal of cancer (Oxford, England : 1990) 2026 Randomized Controlled Trial [Efficacy of octreotide LAR and lanreotide autogel in acromegaly assessed by SAGIT] Núñez-Martínez FJ et al. Revista medica del Instituto Mexicano del Seguro Social 2026 Observational Study The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [(177)Lu]Lu-DOTA-TATE: A post-authorisation safety study Hofland J et al. Journal of neuroendocrinology 2026 Clinical Trial, Phase IV Efficacy and safety of peptide radionuclide therapy with (177)Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N) Okamoto K et al. Journal of gastroenterology 2026 Observational Study Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada Rayson D et al. Neuroendocrinology 2026 Observational Study Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107) Garcia-Carbonero R et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 Randomized Controlled Trial Evaluation of Reduced Single-Photon Emission Computed Tomography Imaging Protocols and Software Variability in (177)Lu-DOTATATE Dosimetry: Protocol for an Exploratory Observational Trial Yagihashi T et al. JMIR research protocols 2026 Observational Study A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors Becx MN et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2026 Randomized Controlled Trial Ga-68-Edotreotide PET/CT SSTR Total Tumor Volume as a Predictor of Outcome in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Gallicchio R et al. Cancer control : journal of the Moffitt Cancer Center 2026 Observational Study Targeted β(-)-Particle Plus Conversion and Auger-Electron Therapy with (161)Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study Fricke JG et al. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026 Randomized Controlled Trial One vs Five Days of Octreotide Infusion for Acute Esophageal Variceal Bleeding: A Randomized Controlled Trial Chirapongsathorn S et al. The American journal of gastroenterology 2026 Randomized Controlled Trial [(177)Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial Albert NL et al. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026 Clinical Study Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial Kolodziej M et al. Frontiers in endocrinology 2025 Randomized Controlled Trial PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Puranik AD et al. BMC cancer 2025 Clinical Study (177)Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial Xu J et al. Annals of oncology : official journal of the European Society for Medical Oncology 2025 Randomized Controlled Trial Phase II Study of (177)Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers Lin FI et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Clinical Trial, Phase II Prostate cancer detection with [(99m)Tc]Tc-HYNIC-iPSMA SPECT: The Australian experience Currie G et al. Radiography (London, England : 1995) 2025 Observational Study Dosing patterns, healthcare resource utilization and costs among acromegaly patients who consistently use lanreotide and injectable octreotide Quock TP et al. Journal of comparative effectiveness research 2025 Observational Study Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol Chhajlani S et al. BMJ open 2025 Clinical Study Psycho-Oncological Screening Identifies High-Risk Subgroups Among Neuroendocrine Tumor Patients Undergoing PRRT with [177Lu]Lu-DOTATATE: Implications for Survival Kreppel B et al. Nuklearmedizin. Nuclear medicine 2025 Clinical Study Postmarketing safety surveillance of 177 Lu-DOTA-TATE (LUTATHERA): an observational, pharmacovigilance study leveraging FAERS database Wu X et al. Nuclear medicine communications 2025 Observational Study Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly Glatard A et al. Clinical pharmacokinetics 2025 Randomized Controlled Trial
More cited research Conditions researched Anemia Anti-aging & longevity Atherosclerosis, cardiovascular disease & high blood pressure Delayed gastric emptying on GLP-1 medicines Dementia, Alzheimer's & cognitive decline Diabetic retinopathy and glaucoma Fat loss, obesity & body recomposition Fatty liver & elevated liver enzymes Gallbladder and gallstones Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers Heart repair: after heart attack, heart failure & enlarged heart Hyperparathyroidism Immune system (general) Insulin resistance, prediabetes & type 2 diabetes Kidney protection (CKD, diabetic kidney, lupus kidney) Low blood pressure and orthostatic hypotension Lung health, asthma & COPD Lupus (SLE) Lymphedema and swelling Migraine Muscle gain, sarcopenia & building muscle after 40 Muscle disease (myopathy) Neuropathy and CRPS Pancreatitis (after the acute phase) PCOS Post-surgical inflammation and surgery recovery POTS and dysautonomia Sleep problems (incl. insomnia on peptides) Tendon, ligament, muscle & joint injuries (incl. athletes) Thyroid problems Varicose veins Related compounds FAQ What is Octreotide? An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
How many registered human trials study Octreotide? The PeptideWhiz trial index lists 256 registered trials for Octreotide, the most recent from 2027.
How much published research exists on Octreotide? The PeptideWhiz paper index links 1159 PubMed papers to Octreotide; by study type, 1285 human and 35 animal studies.
Which conditions is Octreotide researched for? Anemia, Anti-aging & longevity, Atherosclerosis, cardiovascular disease & high blood pressure, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Diabetic retinopathy and glaucoma, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Gallbladder and gallstones, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Heart repair: after heart attack, heart failure & enlarged heart, Hyperparathyroidism, Immune system (general), Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Low blood pressure and orthostatic hypotension, Lung health, asthma & COPD, Lupus (SLE), Lymphedema and swelling, Migraine, Muscle gain, sarcopenia & building muscle after 40, Muscle disease (myopathy), Neuropathy and CRPS, Pancreatitis (after the acute phase), PCOS, Post-surgical inflammation and surgery recovery, POTS and dysautonomia, Sleep problems (incl. insomnia on peptides), Tendon, ligament, muscle & joint injuries (incl. athletes), Thyroid problems, Varicose veins.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).
Reported dosing ranges from research